Abiopharma

A New Press Release from Elicio Therapeutics

Gallman Cari 🟡 adjusted position in 60.4K shares (5 derivative) of BRISTOL MYERS SQUIBB CO (BMY) at $60.13 Transaction Date: Mar 10, 2026 | Filing ID: 000003

Director Valantine Hannah 🟡 adjusted position in 8.7K shares (1 derivative) of BridgeBio Pharma, Inc. (BBIO) at $72.00 ($1.1M) Transaction Date: Mar 10, 2026 | Filing ID: 000260

Voting Rights and Shares Capital of the Company

Poole Ahn Amanda 🟡 adjusted position in 33.8K shares (5 derivative) of BRISTOL MYERS SQUIBB CO (BMY) at $60.13 Transaction Date: Mar 10, 2026 | Filing ID: 000002

PHH Mortgage Receives 2025 Fannie Mae Star Performer Award for Servicing Excellence

DHI Group to Participate in the Sidoti Small Cap Conference on March 19, 2026

BuzzFeed, Inc. Reports Q4 and Full Year 2025 Results

Amrize Publishes Annual Report for Fiscal Year 2025

Redwood Trust Announces First Quarter 2026 Common and Preferred Dividends

BrightView Declares Ninth Consecutive Cash Dividend Payment on Preferred Stock

Dover Announces First Quarter 2026 Earnings Release Date, Conference Call and Webcast

WM Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

RYAM CEO Scott Sutton to Present at Gabelli Funds’ 17th Annual Specialty Chemicals Symposium

Vertex Achieves Remarkable Growth, Sets New Industry Standard with ServiceTitan